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Medication Use to Reduce Risk of Breast Cancer
US Preventive Services Task Force
Recommendation Statement
US Preventive Services Task Force
IMPORTANCE Breast cancer is the most common nonskin cancer among women in the
United States and the second leading cause of cancer death. Themedian age at diagnosis
is 62 years, and an estimated 1 in 8 womenwill develop breast cancer at some point
in their lifetime. African American women are more likely to die of breast cancer compared
with women of other races.
OBJECTIVE To update the 2013 US Preventive Services Task Force (USPSTF) recommendation
onmedications for risk reduction of primary breast cancer.
EVIDENCE REVIEW The USPSTF reviewed evidence on the accuracy of risk assessment
methods to identify womenwho could benefit from risk-reducingmedications for breast
cancer, as well as evidence on the effectiveness, adverse effects, and subgroup variations of
these medications. The USPSTF reviewed evidence from randomized trials, observational
studies, and diagnostic accuracy studies of risk stratificationmodels in womenwithout
preexisting breast cancer or ductal carcinoma in situ.
FINDINGS The USPSTF found convincing evidence that risk assessment tools can predict the
number of cases of breast cancer expected to develop in a population. However, these risk
assessment tools performmodestly at best in discriminating between individual womenwho
will or will not develop breast cancer. The USPSTF found convincing evidence that
risk-reducingmedications (tamoxifen, raloxifene, or aromatase inhibitors) provide at least a
moderate benefit in reducing risk for invasive estrogen receptor–positive breast cancer in
postmenopausal women at increased risk for breast cancer. The USPSTF found that the
benefits of taking tamoxifen, raloxifene, and aromatase inhibitors to reduce risk for breast
cancer are no greater than small in women not at increased risk for the disease. The USPSTF
found convincing evidence that tamoxifen and raloxifene and adequate evidence that
aromatase inhibitors are associated with small to moderate harms. Overall, the USPSTF
determined that the net benefit of taking medications to reduce risk of breast cancer is larger
in womenwho have a greater risk for developing breast cancer.
CONCLUSIONS AND RECOMMENDATION The USPSTF recommends that clinicians offer to
prescribe risk-reducingmedications, such as tamoxifen, raloxifene, or aromatase inhibitors,
to womenwho are at increased risk for breast cancer and at low risk for adverse medication
effects. (B recommendation) The USPSTF recommends against the routine use of
risk-reducingmedications, such as tamoxifen, raloxifene, or aromatase inhibitors, in women
who are not at increased risk for breast cancer. (D recommendation) This recommendation
applies to asymptomatic women 35 years and older, including womenwith previous benign
breast lesions on biopsy (such as atypical ductal or lobular hyperplasia and lobular carcinoma
in situ). This recommendation does not apply to womenwho have a current or previous
diagnosis of breast cancer or ductal carcinoma in situ.
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T heUSPreventiveServicesTaskForce (USPSTF)makes rec-ommendations about theeffectivenessof specific preven-tivecare services forpatientswithoutobvious relatedsigns
or symptoms.
Itbases itsrecommendationsontheevidenceofboththebenefits
andharmsoftheserviceandanassessmentofthebalance.TheUSPSTF
doesnot consider the costs of providing a service in this assessment.
TheUSPSTFrecognizes that clinicaldecisions involvemorecon-
siderations than evidence alone. Clinicians should understand the
evidence but individualize decision making to the specific patient
or situation. Similarly, the USPSTF notes that policy and coverage
decisions involve considerations in addition to theevidenceof clini-
cal benefits and harms.
Summary of Recommendations and Evidence
The USPSTF recommends that clinicians offer to prescribe risk-
reducingmedications, such as tamoxifen, raloxifene, or aromatase
inhibitors, towomenwhoareat increased risk forbreast cancer and
at low risk for adverse medication effects (B recommendation)
(Figure 1).
Figure 1. USPSTF Grades and Levels of Evidence
What the USPSTF Grades Mean and Suggestions for Practice
Grade Definition
A The USPSTF recommends the service. There is high certainty that the net benefit is substantial. Offer or provide this service.
Suggestions for Practice
B The USPSTF recommends the service. There is high certainty that the net benefit is moderate, or
there is moderate certainty that the net benefit is moderate to substantial.
Offer or provide this service.
C
The USPSTF recommends selectively offering or providing this service to individual patients
based on professional judgment and patient preferences. There is at least moderate certainty
that the net benefit is small.
Offer or provide this service for selected
patients depending on individual
circumstances.
D The USPSTF recommends against the service. There is moderate or high certainty that the service
has no net benefit or that the harms outweigh the benefits.
Discourage the use of this service.
I statement
The USPSTF concludes that the current evidence is insufficient to assess the balance of benefits
and harms of the service. Evidence is lacking, of poor quality, or conflicting, and the balance of
benefits and harms cannot be determined.
Read the Clinical Considerations section
of the USPSTF Recommendation
Statement. If the service is offered,
patients should understand the
uncertainty about the balance of benefits
and harms.
USPSTF Levels of Certainty Regarding Net Benefit
Level of Certainty Description
High
The available evidence usually includes consistent results from well-designed, well-conducted studies in representative primary care
populations. These studies assess the effects of the preventive service on health outcomes. This conclusion is therefore unlikely to be
strongly affected by the results of future studies.
Moderate
The available evidence is sufficient to determine the effects of the preventive service on health outcomes, but confidence in the estimate
is constrained by such factors as 
the number, size, or quality of individual studies.
inconsistency of findings across individual studies.
limited generalizability of findings to routine primary care practice.
lack of coherence in the chain of evidence.
As more information becomes available, the magnitude or direction of the observed effect could change, and this change may be large
enough to alter the conclusion.
The USPSTF defines certainty as “likelihood that the USPSTF assessment of the net benefit of a preventive service is correct.” The net benefit is defined as
benefit minus harm of the preventive service as implemented in a general, primary care population. The USPSTF assigns a certainty level based on the nature
of the overall evidence available to assess the net benefit of a preventive service.
Low
The available evidence is insufficient to assess effects on health outcomes. Evidence is insufficient because of
the limited number or size of studies.
important flaws in study design or methods.
inconsistency of findings across individual studies.
gaps in the chain of evidence.
findings not generalizable to routine primary care practice.
lack of information on important health outcomes.
More information may allow estimation of effects on health outcomes.
USPSTF indicates US Preventive Services Task Force.
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The USPSTF recommends against the routine use of risk-
reducingmedications, such as tamoxifen, raloxifene, or aromatase
inhibitors, in women who are not at increased risk for breast can-
cer. (D recommendation)
See the Clinical Considerations section for additional informa-
tion about risk assessment.
Rationale
Importance
Breast cancer is the most common nonskin cancer among women
in theUnitedStatesand thesecond leadingcauseof cancerdeath.1,2
The median age at diagnosis is 62 years,1 and an estimated 1 in 8
women will develop breast cancer at some point in their lifetime.2
AfricanAmericanwomenaremore likely todieofbreastcancercom-
pared with women of other races.1
Assessment of Breast Cancer Risk Status
The USPSTF found convincing evidence that available risk assess-
ment tools can predict the number of cases of breast cancer ex-
pected to develop in a population. However, these risk assessment
tools perform modestly at best in discriminating between indi-
vidual womenwhowill or will not develop breast cancer over time.
Overall, theUSPSTFdetermined that thenetbenefit of takingmedi-
cations to reduce risk of breast cancer is larger inwomenwhohave
a greater risk for developing breast cancer.
Potential Benefits of Risk-ReducingMedications
TheUSPSTF found convincing evidence that risk-reducingmedica-
tions (tamoxifen, raloxifene,oraromatase inhibitors)provideat least
a moderate benefit in reducing risk for invasive estrogen receptor
(ER)–positive breast cancer in postmenopausal women at in-
creased risk for breast cancer (Table).
Both tamoxifenand raloxifene can reduce riskof some typesof
skeletal fractures, independent from the risk of breast cancer.
TheUSPSTF found that the benefits of taking tamoxifen, raloxi-
fene, andaromatase inhibitors to reduce risk forbreast cancerareno
greater than small in women not at increased risk for the disease.
Potential Harms of Risk-ReducingMedications
The USPSTF found convincing evidence that tamoxifen and raloxi-
feneareassociatedwithsmall tomoderateharms.Tamoxifenandral-
oxifene increase risk for venous thromboembolic events (VTEs); ta-
moxifen increases riskmorethanraloxifene(Table), andthepotential
for harms are greater in older women than in younger women. The
USPSTFalso foundadequateevidence that tamoxifen,butnot ralox-
ifene, increases risk for endometrial cancer in womenwith a uterus.
Tamoxifenalso increases riskofcataracts.Vasomotorsymptoms(hot
flashes) are a common adverse effect of bothmedications.
The USPSTF found adequate evidence that the harms of aro-
matase inhibitorsarealsosmall tomoderate.Theseharms includeva-
somotorsymptoms,gastrointestinalsymptoms,musculoskeletalpain,
andpossiblecardiovascularevents, suchasstroke.Aromatase inhibi-
tors do not reduce, andmay even increase, risk of fractures.
USPSTF Assessment
TheUSPSTFconcludeswithmoderatecertaintythat there isamoder-
atenetbenefit fromtakingtamoxifen, raloxifene,oraromatase inhibi-
torstoreduceriskof invasivebreastcancer inwomenat increasedrisk.
The USPSTF concludes with moderate certainty that the po-
tential harms of taking tamoxifen, raloxifene, and aromatase
Table. Benefits and Harms of Risk-ReducingMedications Estimated FromMeta-analysis of Randomized,
Placebo-Controlled Trialsa,b
Outcome Tamoxifen Raloxifene Aromatase Inhibitors
Benefits: Events Reduced (95% CI)c
Breast cancer
Invasive 7 (4-12) 9 (3-15) 16 (8-24)
ER+ 8 (4-13) 8 (4-13) 15 (8-20)
ER− ND ND ND
Noninvasive ND ND ND
Mortality
Breast cancer ND NR NR
All-cause ND ND ND
Fracture
Vertebral ND 7 (5-9) ND
Nonvertebral 3 (0.2-5) ND ND
Harms: Events Increased (95% CI)c
Vascular
Venous thromboembolic event 5 (2-9) 7 (0.3-17) ND
Deep vein thrombosis ND ND NR
Pulmonary embolism ND ND NR
Coronary heart disease events ND ND ND
Other
Endometrial cancer 4 (1-8) ND ND
Cataracts 26 (5-50)d ND ND
Abbreviations: ER−, estrogen
receptor–negative; ER+, estrogen
receptor–positive; ND, no difference;
NR, not reported.
a See Nelson et al.3,4
b Trials included womenwhose 5-year
risk of breast cancer may have been
lower than 3%.
c Per 1000women over 5 years
of use.
dResults from the National Surgical
Adjuvant Breast and Bowel Project
Study of Tamoxifen and Raloxifene
(STAR) trial.
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inhibitors to reduce riskofbreast canceroutweigh thepotentialben-
efits in women not at increased risk for the disease.
Clinicians should discuss the limitations of current clinical risk
assessment tools for predicting an individual’s future risk of breast
cancer when discussing the benefits and harms of risk-reducing
medications with women.
Clinical Considerations
Patient Population Under Consideration
This recommendationapplies toasymptomaticwomen35yearsand
older, including women with previous benign breast lesions on bi-
opsy (such as atypical ductal or lobular hyperplasia and lobular car-
cinoma in situ) (Figure 2). This recommendation does not apply to
women who have a current or previous diagnosis of breast cancer
or ductal carcinoma in situ (DCIS).
Assessment of Risk for Breast Cancer
Various methods are available to identify women at increased risk
for breast cancer, including formal clinical risk assessment tools or
assessing breast cancer risk factors without using a formal tool.
Numerous risk assessment tools, such as the National Cancer
Institute (NCI)BreastCancerRiskAssessmentTool,5estimateawom-
an’s risk of developing breast cancer over the next 5 years. There is
no single cutoff for defining increased risk for all women. Women
at greater risk, such as those with at least a 3% risk for breast can-
cer in the next 5 years, are likely to derive more benefit than harm
fromrisk-reducingmedications6 andshouldbeoffered thesemedi-
cations if their risk of harms is low. Some women at lower risk for
breast cancer have also been included in trials documenting re-
duced risk for breast cancer when taking tamoxifen, raloxifene, or
aromatase inhibitors.3,4 However, when balancing the harms asso-
ciatedwith thesemedications, the net benefit will be lower among
women at lower risk.
Alternatively, cliniciansmayuse combinationsof risk factors (in-
cludingsomeriskfactorsnot includedinriskassessmenttoolsbutthat
wouldhavepermittedenrollment insomeof the risk reduction trials)
to identify women at increased risk. Some examples of combina-
tions ofmultiple risk factors in women at increased risk include (but
arenot limitedto)age65yearsorolderwith1 first-degreerelativewith
breast cancer; 45 years or older with more than 1 first-degree rela-
tivewithbreastcanceror 1 first-degreerelativewhodevelopedbreast
cancerbeforeage50years;40yearsorolderwitha first-degree rela-
tivewith bilateral breast cancer; presence of atypical ductal or lobu-
lar hyperplasia or lobular carcinoma in situ on a prior biopsy.
Womenwith documented pathogenicmutations in the breast
cancer susceptibility 1 and2genes (BRCA1/2) andwomenwithahis-
tory of chest radiation therapy (such as for treatment of childhood
or adolescent Hodgkin or non-Hodgkin lymphoma) are at espe-
cially high risk for breast cancer. The cumulative absolute risk of de-
veloping breast cancer in awomanwho received chest radiation at
Figure 2. Clinical Summary: Medication Use to Reduce Risk of Breast Cancer
Population
Recommendation 
Women aged ≥35 y at increased risk for breast cancer
Offer to prescribe risk-reducing medications, such as tamoxifen,
raloxifene, or aromatase inhibitors
Grade: B 
Women aged ≥35 y not at increased risk for breast cancer
Do not routinely use risk-reducing medications, such as
tamoxifen, raloxifene, or aromatase inhibitors
Grade: D
Risk Assessment
Risk-Reducing
Medications
For a summary of the evidence systematically reviewed in making this recommendation, the full recommendation statement, and supporting documents, please
go to https://www.uspreventiveservicestaskforce.org.   
Various methods are available to identify women at increased risk for breast cancer, including formal clinical risk assessment tools
or assessing breast cancer risk factors without using a formal tool.
The USPSTF does not endorse any particular risk-prediction tool. The National Cancer Institute Breast Cancer Risk Assessment Tool
and the Breast Cancer Surveillance Consortium Risk Calculator are based on models tested in US populations and are publicly available.
There is no single cutoff for defining increased risk for all women.
Alternatively, clinicians may use combinations of risk factors to identify women at increased risk. Some examples of combinations of
multiple risk factors in women at increased risk include (but are not limited to): age 65 years or older with 1 first-degree relative with
breast cancer; age 45 years or older with more than 1 first-degree relative with breast cancer or 1 first-degree relative who developed
breast cancer before age 50 years; age 40 years or older with a first-degree relative with bilateral breast cancer; presence of atypical
ductal or lobular hyperplasia or lobular carcinoma in situ on a prior biopsy. 
When considering prescribing breast cancer risk–reducing medications, the potential benefit of risk reduction of breast cancer must
be balanced against the potential harms of adverse medication effects.
Tamoxifen, raloxifene, and aromatase inhibitors all reduce primary breast cancer risk in postmenopausal women. Use of raloxifene
and aromatase inhibitors is indicated only in postmenopausal women; only tamoxifen is indicated for risk reduction of primary
breast cancer in premenopausal women.
Relevant USPSTF 
Recommendations
The USPSTF has made recommendations on screening for breast cancer and for risk assessment, genetic counseling, and genetic
testing for BRCA genetic mutations.
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age25 years increases fromanestimated 1.4%at age35 years to an
estimated 29% by age 55 years,7 although this may vary by treat-
ment regimen. Women who carry a BRCA1mutation have a cumu-
lativeriskforbreastcancerof72%byage80years;womenwhocarry
a BRCA2mutation have a 69% cumulative risk8 (compared with a
12% lifetime risk in thegeneral population9).Womenwhocarry the
BRCA1mutation tend to develop estrogen receptor (ER)–negative
breast cancer,10 while womenwho carry the BRCA2mutation tend
todevelopER-positivebreastcancer.However, theUSPSTFwasnot
able to find sufficient evidence on the benefits and harms of risk-
reducing medications in women with BRCA1/2 gene mutations or
womenwithahistoryofchestradiation,andthecomprehensiveman-
agement of these risk factors is beyond the scope of this Recom-
mendationStatement.Further informationoncomprehensiveman-
agementstrategies, includingrisk-reducingmedications, forwomen
with these conditions is available from other organizations.
Women not at increased risk for breast cancer, such aswomen
younger than60yearswithnoadditional risk factors forbreast can-
cer, or womenwith a low 5-year risk of breast cancer should not be
routinely offeredmedications to reduce risk of breast cancer, since
the risk of harms from thesemedications likely outweighs their po-
tential benefit.
Although evidence on the best interval at which to reassess
risk and indications for risk-reducing medications is not available, a
pragmatic approach would be to repeat risk assessment when
there is a significant change in breast cancer risk factors, for
instance when a family member is diagnosed with breast cancer or
when there is a new diagnosis of atypical hyperplasia or lobular car-
cinoma in situ on breast biopsy.
Whenconsideringprescribingbreastcancer risk-reducingmedi-
cations, potential benefit of risk reductionof breast cancermustbe
balanced against the potential harms of adverse medication ef-
fects. Seebelow formore informationonpotential harms fromrisk-
reducingmedications.
Risk-ReducingMedications
A systematic review of trials conducted for the USPSTF found that
compared with placebo, tamoxifen reduced the incidence of inva-
sive breast cancer by 7 events per 1000women over 5 years (95%
CI,4-12), andraloxifene reduced incidenceby9events (95%CI,3-15)
per 1000women over 5 years.3,4 Given that the study participants
in tamoxifenvsplaceboandraloxifenevsplacebo trialsdifferedwith
respect to breast cancer risk and age, direct comparisons of effec-
tiveness between tamoxifen and raloxifene cannot bemade based
on these placebo-controlled trials. However, the large Study of
Tamoxifen and Raloxifene (STAR) trial, which directly compared ta-
moxifen with raloxifene, found that tamoxifen reduced breast can-
cer riskmore than raloxifene after long-term follow-up3 (Table). For
womenwith a predicted 5-year breast cancer risk of 3% or greater,
the absolute benefits are likely even higher. Tamoxifen and raloxi-
fene have been found to reduce risk for nonvertebral and vertebral
fractures, respectively.3However, useof tamoxifenand raloxifene is
also associated with increased risk for VTEs and vasomotor symp-
toms. Tamoxifen also increases the risk for endometrial cancer and
cataracts.Theserisksare increased inolderwomen,althoughwomen
whohavehadahysterectomyarenot at risk for endometrial cancer.
Aromatase inhibitorswere found to reduce the incidenceof in-
vasive breast cancer by 16 events per 1000 women over 5 years
(Table).3 Aswith tamoxifen and raloxifene, these absolute benefits
are likely evenhigher forwomenwith apredictedbreast cancer risk
of 3%or greater. Harms of aromatase inhibitors include vasomotor
symptoms, gastrointestinal symptoms, and musculoskeletal pain.
Data on harms of aromatase inhibitors for the primary risk reduc-
tionofbreast cancerare limited,especially long-termharms.A trend
toward increased cardiovascular events (such as transient ische-
micattackandcerebrovascularaccident)hasbeenobserved insome
aromatase inhibitor trials for treatment of womenwith early-stage
breast cancer (orDCIS).3,11,12 Youngerwomenwithno risk factors for
cardiovascular disease are less likely to have a cardiovascular event
witharomatase inhibitor treatment.Aromatase inhibitorsdonot re-
duce, andmay even increase, risk of fractures.
Tamoxifen, raloxifene, and aromatase inhibitors all reduce pri-
mary breast cancer risk in postmenopausal women. Use of raloxi-
fene and aromatase inhibitors is indicated only in postmenopausal
women; only tamoxifen is indicated for risk-reduction of primary
breast cancer in premenopausal women.
Duration ofMedication Use and Persistence of Effects
In trials, participants typically used risk-reducingmedications for 3
to 5 years.3 Benefits of tamoxifen have been found to persist up to
8 years beyond discontinuation,13,14 whereas risk for VTEs and en-
dometrial cancer return to baseline after discontinuation of
tamoxifen.15 Data on similarly long-term persistence of effects are
not available for raloxifene or aromatase inhibitors.
Additional Approaches to Prevention
The USPSTF has made recommendations on screening for breast
cancer16 and for risk assessment, genetic counseling, and genetic
testing for BRCA genetic mutations.17 The NCI and the Centers for
Disease Control and Prevention provide information about poten-
tial ways to reduce risk of cancer, including lifestyle and diet
changes.18,19
Useful Resources
The USPSTF does not endorse any particular risk prediction tool.
However, the NCI Breast Cancer Risk Assessment Tool5 and the
Breast Cancer Surveillance ConsortiumRisk Calculator20 are based
onmodels tested inUSpopulations andarepublicly available for cli-
nicians and patients to use as part of the process of shared, in-
formeddecision-makingabout taking risk-reducingmedications for
breastcancer.Both toolshavebeencalibrated inUSpopulations,but
their discriminatory accuracy of predicting which women will de-
velop breast cancermay bemore limited and there is no single cut-
off for defining increased risk for all women.
Other Considerations
Implementation
Prescribing risk-reducing medications for breast cancer is an un-
common practice among primary care clinicians. Based on limited
survey data, 10% to 30% (depending on medication type) of pri-
mary care clinicians report ever prescribing risk-reducing medica-
tions for primary prevention of breast cancer, and most have only
done so a few times.21-23 The reporteduseof risk-reducingmedica-
tions among women is also relatively low; 1 meta-analysis of 26
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studies found that overall, 16.3% of women at increased risk for
breast cancer used risk-reducingmedications.24 Although only ex-
ploratory,anumberofstudieshavesuggestedthatevenwomenwho
are well informed about the risks and benefits have relatively little
interest in taking risk-reducingmedications forbreast cancerandare
primarily concerned with potential harms.25-29 When considering
prescribing risk-reducing medications for breast cancer, clinicians
shoulddiscuss eachwoman’s personal values andpreferenceswith
respect tobreast cancer risk reduction, in addition towhat is known
about her personal risk for breast cancer and the potential benefits
and harms of medications.
Research Needs and Gaps
More research is needed tobetter identifywhich individualwomen
at increased risk for breast cancer could best benefit from risk-
reducingmedications. In particular, studies are needed that evalu-
ate howmedicationsmay reduce breast cancer risk inwomenwho
are carriers of pathogenicBRCA1orBRCA2mutations. Additionally,
given the higher breast cancer mortality rates in African American
women, studies that include sufficient numbers of African Ameri-
canwomenareneeded tobetter understandhowmedicationsmay
reduce risk in these women. Although currently available risk as-
sessment tools can identify thenumberof casesofbreast cancerex-
pectedtoarise inagivenpopulation,better tools forpredictingbreast
cancer risk in individual women are needed. Additionally, longer-
term follow-up isneeded for studiesof raloxifeneandaromatase in-
hibitors to better understand thepersistenceof bothbreast cancer
risk reductioneffectsandpotentialharmsfromthemedications.Lon-
ger-term data on harms of aromatase inhibitors for the risk reduc-
tionofprimarybreastcancerarealsoneeded.This informationcould
help clinicians weigh the benefits and harms of individual medica-
tions with their patients.
Discussion
Burden of Disease
Breast cancer is themost common nonskin cancer and the second
leading cause of cancer death in women.2 In 2018, an estimated
266 120newcasesofbreast cancerwerediagnosed inwomen in the
UnitedStates, representing30%ofall newcancer cases inwomen.2
Anestimated40920women in theUnitedStatesdiedofbreastcan-
cer, representing 14%ofall cancerdeaths inwomen.2Basedondata
from 2008 to 2014, the 5-year survival rate of breast cancer is an
estimated89.7%, ranging from98.7%whencancer is diagnosedat
localized stages to27%whendiagnosis occurs in the context of dis-
tantmetastases.1 Although incidence rates are similar amongwhite
andAfricanAmericanwomen(128.6vs 126.9casesper 100000per-
sons, respectively),mortality rates arehigher amongAfricanAmeri-
canwomen (28.7deathsper 100000AfricanAmericanpersons vs
20.3 deaths per 100000white persons).1 Incidence rates have in-
creased amongAsian/Pacific Islander, non-Hispanic AfricanAmeri-
can, and Hispanic women but have remained stable among non-
Hispanic white and American Indian/Alaskan Native women.9
Scope of Review
The USPSTF reviewed evidence on the accuracy of risk assessment
methods to identify women who could benefit from risk-reducing
medications for breast cancer, as well as evidence on the effective-
ness, adverse effects, and subgroup variations of thesemedications
(specifically, theselectiveERmodulatorstamoxifenandraloxifeneand
thearomataseinhibitorsexemestaneandanastrozole).3,4TheUSPSTF
reviewedevidencefromrandomizedtrials,observationalstudies,and
diagnosticaccuracystudiesofriskstratificationmodels inwomenwith-
out preexisting breast cancer or DCIS. Studies that includedwomen
withpathogenicBRCA1/2geneticmutationswere included in the re-
viewcriteria;however, studies tounderstandthebenefitsandharms
in this populationwere limited.
Effectiveness of Risk AssessmentModels
The USPSTF reviewed evidence from 25 good- and fair-quality
studies on 18 risk stratification models (n >5000000).3,4 Models
reviewed included the Gail,30-36 Breast Cancer Surveillance
Consortium,37-39 Rosner-Colditz,40-43 Tyrer-Cuzick,44-47
Chlebowski,48 and Italian49-51models, aswell as variations of these
models that focuson specific subpopulationsor that includenewer
data on breast density or benign breast disease.3
The original Gailmodel, the firstmodel used clinically, includes
age, age at first menstruation, age at first childbirth, family history
of breast cancer in first-degree relatives, number of prior breast bi-
opsies, andhistoryof atypical hyperplasia.30The current versionof
the Gail model is used in the Breast Cancer Risk Assessment Tool,
which ispublicly accessible through theNCIwebsite.5Expandingon
the Gail model, newer models include race/ethnicity, prior false-
positivemammography resultsorbenignbreastdisease,bodymass
index or height, estrogen and progestin use, history of breastfeed-
ing,menopause status or age, smoking, alcohol use, physical activ-
ity, education, breast density, and diet.
Severalmodelshavebeentested in largeUSpopulations ingood-
qualitystudies that reportedonly lowtomodestaccuracy.TheBreast
CancerSurveillanceConsortiummodelwasderived frommore than
11 638 breast cancer cases that developed among a cohort of al-
most 2.4 million women.38 The Rosner-Colditz model was derived
from 1761 breast cancer cases that developed among 58 520 par-
ticipants in theNurses’HealthStudy.40Chlebowskiandcolleagues48
developed amodel basedon3236 cases that developed in theWo-
men’sHealth Initiative study.Models from Italy49-51 and theUnited
Kingdom44-47 were also based on large populations but were not
tested in the United States. Although these models demonstrate
good calibration for predicting risk in a population (ie, the pre-
dicted number of breast cancer cases expected to arise in a popu-
lation closely matched the observed number of cases), their dis-
criminatoryaccuracy tocorrectly classify individualwomenwhowill
developbreast cancerover thenext 5years fromthosewhowill not
ismodest at best; the C statistic formostmodels ranged from0.55
to 0.65.3 Models that include breast density, postmenopausal hor-
mone use, and a more extensive family history minimally improve
predictive estimates.
Mostmodels reportperformance slightlybetter thanagealone
as a risk predictor. No studies evaluated optimal ages or frequen-
cies for risk assessment.3
Effectiveness of Risk-ReducingMedications
The USPSTF reviewed evidence from 10 trials that evaluated
the effect of risk-reducing medications for breast cancer.3,4 Four
trials (n = 28 193) evaluated tamoxifen in premenopausal and
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postmenopausalwomenat increased risk forbreast cancer13-15,52-60
(in 1additional trialof low-dosetamoxifen inpostmenopausalwomen
not at increased risk forbreast cancer,61 the lowdosewasnot found
to reduce risk of breast cancer and so was not considered further
by the USPSTF); 2 trials (n = 17 806) evaluated raloxifene in post-
menopausal women not at increased risk for breast cancer,62-78
1 trial (n = 19 747) directly compared raloxifene with tamoxifen
in postmenopausal women at increased risk for breast cancer
(STAR trial79-81), and 2 trials evaluated aromatase inhibitors
(examestane82,83 [n = 4560] and anastrozole84-86 [n = 3864]) in
postmenopausalwomenat increased risk for breast cancer. Eachof
the studies that targetedwomenat increased risk for breast cancer
used different combinations of risk criteria, such as age, family his-
tory, previous abnormal but benign breast pathology, or predicted
breastcancer riskasestimatedbyarisk tool (mostcommonly>1.66%
5-yearpredictedriskofbreastcancer,ascalculatedbytheGailmodel)
to recruitparticipants.Women intheraloxifenetrialswereolder (me-
dian age, 67-67.5 years)3 thanwomen in the other trials, given that
these trials targeted postmenopausal women not at increased risk
for breast cancer (the primary aim was for outcomes other than
breast cancer risk reduction). In contrast, women in the tamoxifen
trials were slightly younger, given that these trials included pre-
menopausal women (median age range, 47-53 years).3
Most trials weremulticenter and conducted in numerous sites
across several countries, predominantly in the United States, the
United Kingdom, and Europe. Most trial participants were white
(84%-97%white in studies that reported this information).3
In trials, all 3 types of medications reduced invasive and
ER-positivebreast cancerbutnotER-negativebreast cancer.3Using
pooled results of the placebo-controlled trials and projecting ben-
efits over 5years, theuseof tamoxifenwould result in 7 fewer cases
of invasive breast cancer (risk ratio [RR], 0.69 [95% CI, 0.59-
0.84])and8fewercasesofER-positivebreastcancer (RR,0.58[95%
CI,0.42-0.81]) (unlessotherwise stated, all numbersof casesareper
1000womenover5yearsofmedicationuse).3Raloxifeneusewould
result in 9 fewer cases of invasive breast cancer (RR, 0.44 [95%CI,
0.24-0.80])and8fewercasesofER-positivebreastcancer (RR,0.33
[95% CI, 0.15-0.73]).3 Furthermore, in addition to reducing breast
cancer risk, tamoxifenand raloxifenewere also found to reduce risk
for fractures: 3 fewer cases of nonvertebral fractures with tamoxi-
fen (RR, 0.66 [95% CI, 0.45-0.98]) and 7 fewer cases of vertebral
fractures with raloxifene (RR, 0.61 [95% CI, 0.53-0.70]).3 Aro-
matase inhibitors would result in 16 fewer cases of invasive breast
cancer (RR, 0.45 [95% CI, 0.26-0.70]) and 15 fewer cases of
ER-positive breast cancer (RR, 0.37 [95% CI, 0.19-0.63]).3 Risk re-
ductionofboth invasive andER-positivebreast cancerpersistedup
to8years after discontinuationof tamoxifenuse in2 trials14,15 (data
on similar length of long-term follow-up for raloxifene and aro-
matase inhibitorsarenotcurrentlyavailable). Effectivenessofmedi-
cations (within trials) didnotvarybyageormenopausal status.One
trial of tamoxifen60 and 1 of anastrazole84 found that risk reduc-
tion was greater for women with a history of breast abnormalities
on biopsy, such as atypical hyperplasia or lobular carcinoma in situ.
Most trials that reported on subpopulation results by 5-year pre-
dicted risk category (as determined by theGailmodel) showed risk
reductionacross all risk categories,3,60,78,80,83 and 1 studyof tamox-
ifenalso indicated that risk reductionmaybegreatest in thehighest-
risk groups.3,60
Althoughcomparisonsof effectivenessbetween the3medica-
tion types (tamoxifen, raloxifene, and aromatase inhibitors) can-
not be made because of the different participant characteristics
amongtheplacebo-controlledtrials, the largeSTARtrialdirectlycom-
pared tamoxifenwith raloxifene forbreast cancer risk reductionand
found that tamoxifen provided a greater risk reduction for invasive
breast canceron long-termfollow-up (5 fewer cases [95%CI, 1-9]).3
Potential Harms of Risk Assessment
and Risk-ReducingMedications
Thesame10trialsdescribedabove that reportedonbenefitsof risk-
reducingmedications forbreastcanceralsoreportedharms.3,4When
comparedwithplacebo, tamoxifenwasassociatedwith5morecases
ofVTEs (RR, 1.93 [95%CI, 1.33-2.68]), 4more cases of endometrial
cancer (RR, 2.25 [95% CI, 1.17-4.41]), and 26 more cases of cata-
racts (RR, 1.22 [95%CI, 1.08-1.48]).3Vasomotorsymptomswerealso
increasedwith tamoxifenuse.Nosignificantdifferenceswere found
withtamoxifenuseonratesofdeepvein thrombosis,pulmonaryem-
bolism, coronary heart disease (CHD) events, or stroke.3
When compared with placebo, raloxifene was associated with
7morecasesofVTE(RR, 1.56[95%CI, 1.11-2.60]).3Vasomotorsymp-
tomswere also increasedwith raloxifene use. No significant differ-
enceswere foundwith raloxifeneuseonratesofCHDevents, stroke,
endometrial cancer,orcataracts.BasedontheSTARtrial,moreharms
were reported with tamoxifen compared with raloxifene: 4 more
cases of VTE (95% CI, 1-7), 3 more cases of deep vein thrombosis
(95%CI, 1-5), 5morecasesof endometrial cancer (95%CI, 2-9), and
15more cases of cataracts (95%CI, 8-22)with tamoxifen thanwith
raloxifene.3Both aromatase inhibitor trials reportedmorevasomo-
tor andmusculoskeletal symptomswith aromatase inhibitors com-
paredwithplacebo.3,82-84Nosignificantdifferences in ratesofVTEs,
deep vein thrombosis, pulmonary embolism, CHD events, stroke,
endometrial cancer, or cataracts were reported for aromatase
inhibitors3,82-84;however,primarypreventionstudieswere likelyun-
derpowered to detect any differences in these outcomes.
Other studies have evaluated the use of aromatase inhibitors
for indications other than risk reductionof primarybreast cancer. A
recentmeta-analysisof trials thatevaluatedextendedaromatase in-
hibitor use for adjuvant treatment in women with early-stage
ER-positive breast cancer suggests a potential increase in cardio-
vascular disease events (odds ratio [OR], 1.18 [95%CI, 1.00-1.40]; 7
studies; n = 16 349) with aromatase inhibitors compared with pla-
cebo or no treatment.12 Another study that compared anastrozole
with tamoxifen in treatingwomenwith DCIS found a significant in-
crease incerebrovascular events (OR,3.36 [95%CI, 1.04-14.18]) and
anonsignificant increase intransient ischemicattacks(OR,2.69[95%
CI,0.90-9.65])withanastrozole.11Anothermeta-analysis thatevalu-
ated studies of aromatase inhibitors compared with tamoxifen for
treatmentof early-stagebreast cancer foundnodifference inVTEs,
cerebrovascular events, or coronaryarterydiseaseevents.87 Litera-
ture from these other studies also suggest that aromatase inhibi-
tors may increase the risk of fractures. Compared with tamoxifen
(which reduces riskof fractures),more fractureswereseenwitharo-
matase inhibitors.11,87 The meta-analysis that evaluated extended
use of aromatase inhibitors compared with placebo or no treat-
ment also found increased fractures associatedwith aromatase in-
hibitors (OR, 1.34 [95%CI, 1.16-1.55]); however, someof thepartici-
pants who received placebo or no treatment in the extended
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treatment period may have received tamoxifen or raloxifene dur-
ing the initial treatment period.12 Given that these studies focused
on treatment ofwomenwith breast cancer or DCIS andwere often
conducted in comparison with tamoxifen rather than placebo, it is
unclear whether these findings are generalizable to a primary pre-
vention population.
Estimate ofMagnitude of Net Benefit
Whether risk-reducing medications provide a net benefit depends
on awoman’s risk for breast cancer, balancedwith the potential for
harms from themedications. Accordingly, the USPSTF recommen-
dation for women at low risk for breast cancer is different than its
recommendation for women at increased risk.
For women at increased risk for breast cancer, the USPSTF
concludes with moderate certainty that taking medications to
reduce risk for breast cancer confer amoderate net benefit. Tamox-
ifen is associated with a greater risk reduction of breast cancer
compared with raloxifene but also with a greater risk of endome-
trial cancer (in women with a uterus), cataracts, and VTEs. These
risks increasewith age. Both tamoxifen and raloxifene decrease risk
of fractures but increase risk of vasomotor symptoms. Aromatase
inhibitors also decrease risk of breast cancer in women at increased
risk for the disease. No studies are currently available that compare
aromatase inhibitors with tamoxifen or raloxifene for risk reduction
of primary breast cancer. Some trials of aromatase inhibitors used
for the treatment of women with early-stage breast cancer or DCIS
suggest that there may be a small increase in cardiovascular dis-
ease, such as stroke, with aromatase inhibitors; compared with
tamoxifen, which reduces risk of fractures, aromatase inhibitors
increase risk of fractures. Whether aromatase inhibitors increase
risk of fractures compared with placebo or no treatment is unclear.
Forwomen not at increased risk for breast cancer, the USPSTF
found that tamoxifen, raloxifene, and aromatase inhibitors provide
only a small benefit in reducing risk for breast cancer but are asso-
ciated with moderate harms. Overall, the USPSTF concludes with
moderate certainty that the potential harms of tamoxifen, raloxi-
fene, and aromatase inhibitors outweigh the potential benefits in
women at low risk of breast cancer.
Response to Public Comment
A draft version of this recommendation statement was posted for
public comment on the USPSTF website from January 15 to Feb-
ruary 11, 2019. In response to comments received, the USPSTF
has clarified that the recommendation statement does not list
every scenario in which medications could be considered but
rather provides information on risk factors that clinicians could
consider in assessing breast cancer risk with their patients. Some
examples are provided to help clinicians understand how to con-
sider these risk factors, but these examples should not be inter-
preted as a definitive list. Some comments expressed concern
that the USPSTF was recommending risk-reducing medications at
a lower 5-year breast cancer risk threshold than previously. The
USPSTF has not lowered its risk threshold for which it has found a
net benefit with risk-reducing medications. Instead, the current
recommendation acknowledges the uncertainty around relying
on a specific threshold calculated by risk assessment tools to
identify women who may benefit from risk-reducing medications
and offers an alternative approach to risk assessment of women,
which includes clinician consideration of clinical risk factors. Some
comments also expressed concern that the USPSTF was no lon-
ger recommending “shared, informed decision making.” As with
all of its recommendations, the USPSTF encourages clinicians to
discuss with patients the risks and benefits of clinical preventive
services in the context of each individual’s personal health values
and preferences when considering a service. Language clarifying
this has been added to the Clinical Considerations section. Last,
as requested, additional information is provided on selection of
medications and menopausal status, and information on harms of
aromatase inhibitors has been clarified in the Clinical Consider-
ations section.
HowDoes Evidence FitWith Biological Understanding?
Tamoxifen and raloxifene are selective ER modulators that inhibit
ERs inbreast tissue and reduce risk for ER-positivebreast cancer by
blocking theproliferationofestrogen-sensitiveepithelial cellswhere
breast cancer can develop. These medications have been ap-
proved by the US Food and Drug Administration for risk reduction
of breast cancer. Aromatase inhibitors inhibit conversion of andro-
gen to estrogen and can reduce risk of ER-positive breast cancer by
decreasing the amount of estrogen available to bind to estrogen-
sensitive epithelial cells. Aromatase inhibitors have been evalu-
ated for risk reductionofbreast cancer inclinical trials, althoughthey
are primarily used for treatment rather than risk reduction of pri-
marycancer.Aromatase inhibitorsarenotcurrentlyapprovedbythe
USFoodandDrugAdministration for risk reductionofprimarybreast
cancer.
Update of Previous USPSTF Recommendation
This recommendations is consistent with the 2013 USPSTF
recommendation.88 As before, the USPSTF recommends offering
risk-reducingmedications towomenat increased risk forbreast can-
cer and at low risk for adversemedication effects (B recommenda-
tion) and recommendsagainst routineuseof risk-reducingmedica-
tions in women not at increased risk (D recommendation). The
current recommendationnow includesaromatase inhibitors among
medications that can reduce risk of breast cancer.
Recommendations of Others
In 2013, the American Society of Clinical Oncology recommended
discussing tamoxifen as an option to reduce risk of breast cancer in
women at increased risk who are 35 years and older. It also recom-
mended that raloxifene and exemestane be discussed as additional
options for risk reduction in postmenopausal women.89 The
National Comprehensive Cancer Network recommends risk-
reducing agents for women 35 years and older and tamoxifen for
premenopausal women only; tamoxifen, raloxifene, anastrozole, or
exemestane may be used in postmenopausal women.90 The
American College of Obstetricians and Gynecologists states that
the risk-reduction agents tamoxifen and raloxifene (in postmeno-
pausal women) may be considered for breast cancer risk reduction
in BRCAmutation carriers.91 Given the protective effects in other
at-risk populations, aromatase inhibitors may be an alternative for
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women who cannot take tamoxifen.91 Postmenopausal women
taking tamoxifen should be closely monitored for symptoms of
endometrial hyperplasia and cancer.92 The American Academy of
Family Physicians supports the 2013 USPSTF recommendation.93
The American Cancer Society does not have formal recommenda-
tions on the use of risk-reducingmedications for breast cancer.
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